01 Growing Shift Toward Presymptomatic Treatment Through Newborn Screening Newborn screening is increasingly becoming an important pathway for expanding the Spinal Muscular Atrophy treatment market because disease-modifying therapies provide the greatest benefit when treatment begins before substantial motor-neuron loss occurs. Earlier genetic identification enables clinicians to initiate treatment before symptoms emerge, improving the potential for survival and motor-function preservation. This is shifting the treatment pathway from symptom-driven diagnosis toward population-level early detection and intervention. In July 2026, the UK government announced that all babies in England would be screened for SMA through a nationwide newborn-screening evaluation programme, with the objective of identifying affected infants before symptoms appear.
02 Expansion of Gene Therapy Across Broader SMA Patient Populations Gene therapy is becoming a more established component of SMA treatment as regulatory frameworks expand its use across wider age groups and disease presentations. This development broadens the addressable treatment population beyond infants and supports greater adoption of one-time genetic interventions alongside established disease-modifying approaches. Continued clinical follow-up is also increasing the evidence base surrounding long-term treatment outcomes and safety. In November 2025, the US FDA approved onasemnogene abeparvovec-brve for adults and pediatric patients aged 2 years and older with SMA associated with confirmed SMN1 mutations.
01 Earlier Diagnosis Increases Demand for Disease-Modifying SMA Therapies Newborn screening allows affected infants to be identified before clinical deterioration, creating a direct pathway from diagnosis to treatment initiation. As screening programmes expand, the number of patients identified during the therapeutic window is expected to increase.
01 High Treatment Costs Limit Broader Access to SMA Therapies The high cost of disease-modifying therapies remains a major restraint because SMA requires long-term clinical management in addition to drug treatment. Payers must consider medication costs, monitoring requirements and continuing multidisciplinary supportive care when determining reimbursement. These economic pressures can restrict treatment access, particularly in healthcare systems with limited rare-disease funding.
01 Expansion of Newborn Screening Creates a Larger Early-Treatment Population Greater screening availability is particularly relevant in regions where delayed diagnosis continues to limit treatment outcomes. In July 2026, England announced nationwide expansion of SMA newborn screening, providing clinicians with a greater opportunity to identify affected babies before symptoms develop.
01 Unequal Global Access and Long-Term Care Requirements Complicate Market Expansion The SMA treatment market faces challenges from uneven availability of therapies, differences in healthcare infrastructure and the need for lifelong multidisciplinary management. Although disease-modifying treatments have substantially changed SMA outcomes, access remains concentrated in better-resourced healthcare systems. Increasing numbers of patients surviving into adulthood also require treatment models that address long-term monitoring and transitions between pediatric and adult care.
January 2026 Novartis Gene Therapies expanded long-term support and follow-up initiatives for Zolgensma (onasemnogene abeparvovec), advancing gene therapy-based SMA treatment programs and patient monitoring efforts.
November 2025 Biogen expanded its SMA treatment portfolio through continued development and commercialization activities for Spinraza (nusinersen), supporting broader patient access and treatment optimization initiatives worldwide.
September 2025 Roche expanded research collaborations focused on next-generation SMA therapies, including approaches targeting improved delivery, treatment timing, and long-term disease management.